ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) has been assigned a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $38.67.
A number of analysts recently issued reports on ABVX shares. Citizens Jmp upgraded ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. JMP Securities restated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.
View Our Latest Stock Report on ABIVAX Société Anonyme
Institutional Investors Weigh In On ABIVAX Société Anonyme
Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $29,000. R Squared Ltd acquired a new position in ABIVAX Société Anonyme in the 4th quarter valued at $36,000. Bank of America Corp DE increased its stake in ABIVAX Société Anonyme by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth approximately $85,000. Finally, Guggenheim Capital LLC purchased a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $92,000. 47.91% of the stock is owned by hedge funds and other institutional investors.
ABIVAX Société Anonyme Trading Up 2.0 %
ABVX stock traded up $0.15 during trading on Monday, reaching $7.49. The company's stock had a trading volume of 231,697 shares, compared to its average volume of 155,412. ABIVAX Société Anonyme has a 1 year low of $5.49 and a 1 year high of $17.02. The company's fifty day moving average is $6.81 and its 200-day moving average is $9.20.
ABIVAX Société Anonyme Company Profile
(
Get Free ReportABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
